Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Launch New Firm for Duchenne Muscular Dystrophy Therapy Jointly with Govt-Backed Fund
February 15, 2013
- Nichi-Iko to Open Representative Office in Thailand on April 1
February 14, 2013
- AZ Takes Over GLP-1 Receptor Agonist Bydureon from Eli Lilly in Japan
February 14, 2013
- Allegra, Allelock Face Stiff Competition from Generics in Anti-Allergic Drug Market
February 14, 2013
- Otsuka Holdings Pharmaceutical Sales Up 3.4% in April-December Thanks to Abilify Sales Hike
February 14, 2013
- Samsca 7.5 mg Tablets Approved: Otsuka
February 14, 2013
- Novartis Will Explain to Doctors that 2009 Article on Diovan Is Invalid: President Mitani
February 13, 2013
- Bristol-Myers, Pfizer Underline Eliquis’s Superiority vs. Warfarin
February 13, 2013
- Novartis Sales Up 2.5% in 2012 Thanks to Rapid Growth in New Fields
February 13, 2013
- Sales of 10 Top European, US Drug Makers See Sharp Declines in 2012 Due to Patent Cliff
February 13, 2013
- Naglazyme Sales and Development Funds Grow for AnGes MG in April-December
February 12, 2013
- Eli Lilly to Discontinue Development of Tabalumab for RA
February 12, 2013
- Will Lotriga Create a New Market or Battle Head to Head with Epadel?
February 12, 2013
- Ethical Drug Sales Down 2.5% in December: Crecon Report
February 8, 2013
- Seikagaku to Initiate PII Trial in Japan of Knee Osteoarthritis Treatment
February 8, 2013
- Chugai Applies for Once-Weekly Herceptin for Postoperative Adjuvant Chemotherapy in Breast Cancer Based on Data from Public Domain
February 8, 2013
- Asahi Kasei Pharma Reports Strong Growth for April-December 2012; Sales of Teribone Break 12 Billion Yen Mark
February 8, 2013
- Pfizer Confident about Joining Top 3 in Japan Generic Sales by around 2015: Unit Chief Matsumori
February 7, 2013
- DSP President Expects Launch of PMDA-WEST, Says Kansai Firms Are at Disadvantage
February 7, 2013
- EMA Approves Otsuka’s Abilify for the Treatment of Manic Episodes in Bipolar I Disorder in Adolescents
February 7, 2013
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…